June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Effect of phakic status on residual peripheral visual islands in patients with retinitis pigmentosa
Author Affiliations & Notes
  • Bani Antonio-Aguirre
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Tapan Patel
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Andrew T Schilling
    Columbia University, New York, New York, United States
  • Hursuong Vongsachang
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Mandeep S Singh
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
    Department of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Bani Antonio-Aguirre None; Tapan Patel None; Andrew Schilling None; Hursuong Vongsachang None; Mandeep Singh Revision Therapeutics, Johnson & Johnson, Third Rock Ventures, Bayer Healthcare, Novartis Pharmaceuticals, W. L. Gore & Associates, Deerfield, Trinity Partners, Kala Pharmaceuticals, Acucela, and Ionis Pharmaceuticals, Code C (Consultant/Contractor), Bayer, Code F (Financial Support)
  • Footnotes
    Support  Foundation Fighting Blindness Career Development Award: CD-RM-0918-0749-JHU
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4658. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bani Antonio-Aguirre, Tapan Patel, Andrew T Schilling, Hursuong Vongsachang, Mandeep S Singh; Effect of phakic status on residual peripheral visual islands in patients with retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4658.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinitis pigmentosa (RP) is typically characterized by progressive peripheral visual field (pVF) loss. PVF loss is a main source of visual disability in RP patients. Therefore, greater understanding of factors that promote this process is required, so that mitigation or treatment strategies can be rationally developed. Although the factors associated with retained pVF are not fully understood, cataract extraction (CE) might influence the magnitude of pVF loss. Here, we leverage a dataset of RP cases to estimate the effect of the phakic status on pVF preservation.

Methods : Goldmann visual fields (GVF) of all eyes were included in a cross-sectional dataset, and those with repeated GVFs in a longitudinal dataset. Eyes were classified by phakic status into phakic and pseudophakic/aphakic. Self-reported symptomatic disease duration (SDD) was extracted from the medical records. The remaining area of pVF (cm2) was calculated using segmentation analysis. Mixed-effects regressions estimated the association of the lens status and pVF.

Results : We included 144 patients and 275 eyes in the cross-sectional dataset. The mean age was 48.6 ± 18 years, and 77.8% (n=214) were phakic. Most eyes (62.8%) had <20 years of SDD. Pseudophakia/aphakia was not associated with a lower baseline pVF (mean difference, -9.33 cm2, SE 14.26; P=0.514), but eyes with SDD >40 years had on average lower retained pVF (mean difference, 56.46 cm2, SE 21.83; P=0.012) than those <20. The longitudinal set included 118 eyes of 59 patients. The follow-up ranged from 1.4 to 6.6 years. Overall, there was a mean loss of 10.64 cm2/year in retained pVF. The retained pVF in pseudophakic/aphakic eyes was significantly lower than in phakic eyes at year 6 of follow-up after adjusting for SDD (mean difference, -75.86 cm2, SE 24.42, P=0.002). There was no effect association between SDD and retained pVF over time.

Conclusions : Lens status might not affect pVF loss in the short term in patients with RP. However, the effects on the rate pVF decline in pseudophakic/aphakic eyes might increase over time.To more fully understand the environmental and genetic factors associated with progressive pVF loss, future studies should prospectively investigate the change in pVF before and after CE and by RP genotype.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×